[go: up one dir, main page]

NO20020391D0 - 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo-[3,4-i]-purin-5-on- derivater - Google Patents

8-Fenyl-6,9-dihydro-[1,2,4]-triazolo-[3,4-i]-purin-5-on- derivater

Info

Publication number
NO20020391D0
NO20020391D0 NO20020391A NO20020391A NO20020391D0 NO 20020391 D0 NO20020391 D0 NO 20020391D0 NO 20020391 A NO20020391 A NO 20020391A NO 20020391 A NO20020391 A NO 20020391A NO 20020391 D0 NO20020391 D0 NO 20020391D0
Authority
NO
Norway
Prior art keywords
purin
triazolo
dihydro
phenyl
derivatives
Prior art date
Application number
NO20020391A
Other languages
English (en)
Other versions
NO20020391L (no
Inventor
Jordi Gracia Ferrer
Joan Feixas Gras
Jose Manuel Prieto Soto
Armando Vega Noverola
Bernat Vidal Juan
Original Assignee
Almirall Prodesfarma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Prodesfarma Sa filed Critical Almirall Prodesfarma Sa
Publication of NO20020391D0 publication Critical patent/NO20020391D0/no
Publication of NO20020391L publication Critical patent/NO20020391L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/22—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20020391A 1999-07-27 2002-01-25 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo [3,4-i]-purin-5-on- derivater NO20020391L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES009901694A ES2166270B1 (es) 1999-07-27 1999-07-27 Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
PCT/EP2000/007062 WO2001007441A1 (en) 1999-07-27 2000-07-24 8-PHENYL-6,9-DIHYDRO-[1,2,4]TRIAZOLO[3,4-i]PURIN-5-ONE DERIVATIVES

Publications (2)

Publication Number Publication Date
NO20020391D0 true NO20020391D0 (no) 2002-01-25
NO20020391L NO20020391L (no) 2002-03-25

Family

ID=8309393

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020391A NO20020391L (no) 1999-07-27 2002-01-25 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo [3,4-i]-purin-5-on- derivater

Country Status (34)

Country Link
US (1) US7034016B2 (no)
EP (1) EP1198464B1 (no)
JP (1) JP2003505461A (no)
KR (1) KR20020022786A (no)
CN (1) CN1198825C (no)
AR (1) AR024969A1 (no)
AT (1) ATE251625T1 (no)
AU (1) AU777571B2 (no)
BG (1) BG106346A (no)
BR (1) BR0012764A (no)
CA (1) CA2380181A1 (no)
CO (1) CO5190717A1 (no)
CZ (1) CZ2002311A3 (no)
DE (1) DE60005838T2 (no)
DK (1) DK1198464T3 (no)
EE (1) EE200200046A (no)
ES (2) ES2166270B1 (no)
HK (1) HK1044332B (no)
HU (1) HUP0202103A3 (no)
IL (1) IL147770A0 (no)
MY (1) MY129590A (no)
NO (1) NO20020391L (no)
NZ (1) NZ516780A (no)
PE (1) PE20010401A1 (no)
PL (1) PL353827A1 (no)
PT (1) PT1198464E (no)
RU (1) RU2258705C2 (no)
SK (1) SK1352002A3 (no)
TR (1) TR200200785T2 (no)
TW (1) TW568912B (no)
UA (1) UA73513C2 (no)
UY (1) UY26258A1 (no)
WO (1) WO2001007441A1 (no)
ZA (1) ZA200200561B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1127506C (zh) * 2001-06-29 2003-11-12 刘宝顺 一种治疗阳痿的新化合物
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
SE0300917D0 (sv) 2003-03-31 2003-03-31 St Jude Medical Multi-chamber pacing system
PT1644021E (pt) * 2003-06-13 2013-01-30 Ironwood Pharmaceuticals Inc Métodos e composições para o tratamento de distúrbios gastrointestinais
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
AU2005243192A1 (en) * 2004-04-29 2005-11-24 Merck & Co., Inc. Azetidine glycine transporter inhibitors
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2005307861B2 (en) * 2004-11-18 2009-11-12 Schering Corporation Methods of using PDE V inhibitors for the treatment of congestive heart failure
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
KR101541791B1 (ko) 2006-05-04 2015-08-04 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0919288A2 (pt) 2008-09-10 2015-12-15 Boehring Ingelheim Internat Gmbh teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20110103968A (ko) 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20240090632A (ko) 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
MX2012014247A (es) 2010-06-24 2013-01-18 Boehringer Ingelheim Int Terapia para la diabetes.
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
ES2934843T3 (es) 2011-07-15 2023-02-27 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
IN2015DN00334A (no) 2012-06-18 2015-06-12 Dart Neuroscience Cayman Ltd
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
CA3087655A1 (en) * 2018-01-04 2019-07-11 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
TWI837171B (zh) * 2018-08-30 2024-04-01 日商鐵勒史東股份有限公司 用於抑制黃嘌呤氧化酶之肼基嘌呤化合物及三唑嘌呤化合物
CN112225761B (zh) * 2020-12-16 2021-03-12 南京颐媛生物医学研究院有限公司 一种嘧啶并三氮唑及其合成方法
EP4305033B1 (en) * 2021-03-09 2025-05-07 Basf Se Tricyclic pesticidal compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
DE3347290A1 (de) * 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
DE69029303T2 (de) * 1989-09-14 1997-05-28 Kyowa Hakko Kogyo Kk 5-Triazolo(3,4-i)purinderivate
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
US5990118A (en) * 1995-02-21 1999-11-23 Yamasa Corporation Purine compounds and xanthine oxidase inhibitors
RS50118B (sr) * 1997-04-25 2009-03-25 Pfizer Inc., Pirazolopirimidinoni koji inhibiraju tip 5 ciklične guanozin 3',5'-monofosfat fosfo-diesteraze (cgmp pde5) za tretman seksualne disfunkcije
WO1999062905A1 (en) * 1998-06-03 1999-12-09 Almirall Prodesfarma, S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
AU2001289782A1 (en) * 2000-08-09 2002-02-18 Almirall Prodesfarma, S.A. Pyrrolotriazolopyrimidinone derivatives

Also Published As

Publication number Publication date
CO5190717A1 (es) 2002-08-29
HUP0202103A2 (en) 2002-10-28
AU6277200A (en) 2001-02-13
DE60005838T2 (de) 2004-08-19
TR200200785T2 (tr) 2002-09-23
AU777571B2 (en) 2004-10-21
PT1198464E (pt) 2004-02-27
US7034016B2 (en) 2006-04-25
HUP0202103A3 (en) 2004-12-28
ES2166270A1 (es) 2002-04-01
MY129590A (en) 2007-04-30
SK1352002A3 (en) 2003-04-01
ATE251625T1 (de) 2003-10-15
AR024969A1 (es) 2002-10-30
CN1198825C (zh) 2005-04-27
CZ2002311A3 (cs) 2003-01-15
HK1044332A1 (en) 2002-10-18
PL353827A1 (en) 2003-12-01
HK1044332B (en) 2004-10-15
EP1198464A1 (en) 2002-04-24
JP2003505461A (ja) 2003-02-12
ES2166270B1 (es) 2003-04-01
PE20010401A1 (es) 2001-04-16
EE200200046A (et) 2003-04-15
UA73513C2 (en) 2005-08-15
KR20020022786A (ko) 2002-03-27
RU2258705C2 (ru) 2005-08-20
NZ516780A (en) 2004-01-30
CN1374962A (zh) 2002-10-16
IL147770A0 (en) 2002-08-14
BR0012764A (pt) 2002-07-02
TW568912B (en) 2004-01-01
NO20020391L (no) 2002-03-25
US20030060627A1 (en) 2003-03-27
WO2001007441A1 (en) 2001-02-01
BG106346A (en) 2002-09-30
ES2208378T3 (es) 2004-06-16
CA2380181A1 (en) 2001-02-01
EP1198464B1 (en) 2003-10-08
ZA200200561B (en) 2003-06-25
DK1198464T3 (da) 2004-02-16
DE60005838D1 (de) 2003-11-13
UY26258A1 (es) 2000-12-29

Similar Documents

Publication Publication Date Title
NO20020391D0 (no) 8-Fenyl-6,9-dihydro-[1,2,4]-triazolo-[3,4-i]-purin-5-on- derivater
DE69915675D1 (de) Triazolo[4,5-d]pyrimidin-derivate
DE60016615D1 (de) Pyrazolo[4,3-d]pyrimidinderivate
IS2461B (is) Pýrróló [2,3-dl]pýrimídín efnasambönd
MA26851A1 (fr) Derives de pyrrolo [2,3-d] pyrimidine
EP1212327B8 (en) Pyrazolopyrimidines as therapeutic agents
DE69800896D1 (de) 8-substituierte-1,3,8-Triazaspiro[4,5]decan-4-onderivate
PT1218378E (pt) Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina
DK0996621T3 (da) Triazolo[4,5-d]pyrimidin-derivater som anti-trombotiske midler
MXPA02003750A (es) Derivados de purina.
ZA200110208B (en) Purine derivatives.
ZA200202849B (en) Purine derivatives.
EE200200080A (et) Imidaso[1,2a]püridiini ja pürasolo[2,3a]püridiiniderivaadid
ZA200203834B (en) Adamantane derivatives.
DE69804273D1 (de) 5h-Thiazolo[3,2-a]pyrimidinderivate
PL354600A1 (en) Naphthyridine derivatives
DE60103909D1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
DE69803653D1 (de) 1,3,8-Triazaspiro[4,5]decan-4-on-derivate
NO20013384D0 (no) Imidazo[4,5-c]pyridin-4-on-derivater
DE69900220D1 (de) Diaza-spiro[3,5]nonan-Derivate
IL140326A0 (en) Protein c derivatives
HUP0003692A3 (en) Pyrimido[4,5-b]indolyl-alkanecarboxamide derivatives
AU6831500A (en) 1h-pirido[3, 4-b]indol-1-one derivatives
SI1198464T1 (en) 8-PHENYL-6,9-DIHYDRO-(1,2,4)TRIAZOLO(3,4-i)PURIN-5-ONE DERIVATIVES
PL352760A1 (en) Oxathiepino[6,5-b